Victory Capital Management Trims Halozyme Therapeutics Stake

Institutional investor reduces position in biopharmaceutical company by 6.9%

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Victory Capital Management Inc. trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 623,029 shares of the biopharmaceutical company's stock after selling 46,430 shares during the quarter.

Why it matters

Institutional investors like Victory Capital Management play a significant role in the stock market, and changes to their holdings can impact a company's share price. Halozyme Therapeutics is a biopharmaceutical firm focused on drug delivery technologies, an area of increasing interest in the healthcare sector.

The details

According to the 13F filing, Victory Capital Management's stake in Halozyme Therapeutics was valued at $45.7 million as of the end of the third quarter. The firm's reduced position represents about 0.53% of the company's outstanding shares. Other large investors have also made changes to their Halozyme holdings, with some increasing and others decreasing their stakes during the same period.

  • Victory Capital Management trimmed its Halozyme Therapeutics holdings during the third quarter of 2026.

The players

Victory Capital Management Inc.

An investment management firm that oversees approximately $157 billion in assets.

Halozyme Therapeutics, Inc.

A biopharmaceutical company that specializes in the development and commercialization of drug delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Victory Capital Management's Halozyme Therapeutics stake reflects broader shifts in institutional investor sentiment around the biopharmaceutical company. While the reasons behind the firm's decision are not explicitly stated, it highlights the fluid nature of institutional holdings and the need for Halozyme to continue executing on its strategic priorities to maintain investor confidence.